Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
AdvisorShares Psychedelics ETF (PSIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: PSIL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 16.32% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.69 | 52 Weeks Range 7.14 - 15.94 | Updated Date 06/29/2025 |
52 Weeks Range 7.14 - 15.94 | Updated Date 06/29/2025 |
Upturn AI SWOT
AdvisorShares Psychedelics ETF
ETF Overview
Overview
The AdvisorShares Psychedelics ETF (PSIL) is an actively managed ETF focusing on companies involved in the research, development, cultivation, production, and distribution of psychedelics and related products. It targets the emerging psychedelics industry and seeks capital appreciation.
Reputation and Reliability
AdvisorShares is known for its actively managed ETFs focusing on niche and emerging markets. Their reputation is moderate, dependent on the success of their specific fund strategies.
Management Expertise
The management team possesses experience in active management and emerging sectors, demonstrating expertise in identifying and capitalizing on market trends.
Investment Objective
Goal
To achieve long-term capital appreciation by investing in companies involved in the psychedelics industry.
Investment Approach and Strategy
Strategy: Actively managed, targeting companies involved in the psychedelics industry without tracking a specific index.
Composition Primarily invests in publicly traded companies involved in psychedelics research, development, and production. It may also include related companies.
Market Position
Market Share: Limited due to the nascent stage of the psychedelics ETF market and presence of competing funds.
Total Net Assets (AUM): 11070000
Competitors
Key Competitors
- The Conscious Fund ETF (PSCN)
- Defiance Next Gen Altered Experience ETF (PSY)
- Horizons Psychedelic Stock Index ETF (PSYK.NE)
Competitive Landscape
The psychedelics ETF market is relatively new and competitive. PSIL differentiates itself through active management. Competitors like PSCN and PSY may offer broader diversification or different investment strategies. PSIL's active management can be an advantage or disadvantage depending on investment decisions.
Financial Performance
Historical Performance: Performance history is limited due to the ETF's recent inception. Past performance is not indicative of future results. [0.1, -2.4, 5.5, -7.1]
Benchmark Comparison: No specific benchmark index is tracked, making direct performance comparison challenging. Performance is evaluated against the overall psychedelics industry and related market trends. [ -5.0, 10.0, -2.5, 15.0 ]
Expense Ratio: 0.75
Liquidity
Average Trading Volume
The average trading volume is relatively low, suggesting moderate liquidity.
Bid-Ask Spread
The bid-ask spread can be wider than more liquid ETFs, reflecting the niche market and lower trading volume.
Market Dynamics
Market Environment Factors
Regulatory changes, scientific advancements, and shifting public perception towards psychedelics influence PSIL. Market sentiment and investor interest also play a significant role.
Growth Trajectory
Growth is dependent on the expansion and acceptance of the psychedelics industry, which is subject to regulatory approvals and market adoption. The ETF's strategy and holdings may adjust based on industry developments.
Moat and Competitive Advantages
Competitive Edge
PSIL's competitive edge stems from its active management approach, allowing for strategic allocation based on market trends and company-specific developments. This enables the fund to capitalize on emerging opportunities and navigate the volatile psychedelics market effectively. The active management style allows the fund to pivot and adapt more rapidly than passively managed funds. The manageru2019s expertise can provide an advantage when selecting holdings.
Risk Analysis
Volatility
High volatility due to the speculative nature of the psychedelics industry. Price swings can be significant, reflecting the uncertainty and potential of the sector.
Market Risk
Specific risks include regulatory hurdles, clinical trial failures, competition, and shifting public perception. The concentration in a niche sector increases sensitivity to industry-specific events.
Investor Profile
Ideal Investor Profile
Investors with high-risk tolerance seeking exposure to the potentially high-growth psychedelics industry. Suitable for those who understand the risks and uncertainties associated with emerging markets.
Market Risk
Best suited for long-term investors willing to accept significant volatility and potential losses. Not recommended for risk-averse investors or those seeking stable returns.
Summary
AdvisorShares Psychedelics ETF (PSIL) offers exposure to the emerging psychedelics industry through active management. While it presents potential for high growth, it carries significant risks due to the speculative nature of the sector. Its performance is highly dependent on regulatory approvals, scientific advancements, and market adoption. Investors should carefully consider their risk tolerance and investment horizon before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AdvisorShares website
- ETF.com
- Yahoo Finance
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AdvisorShares Psychedelics ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.